NASDAQ:ARRY - Array Biopharma Stock Price, Price Target & More

$14.44 -0.85 (-5.56 %)
(As of 04/20/2018 08:25 AM ET)
Previous Close$15.29
Today's Range$14.40 - $15.42
52-Week Range$6.73 - $18.78
Volume2.90 million shs
Average Volume3.66 million shs
Market Capitalization$3.17 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.73

About Array Biopharma (NASDAQ:ARRY)

Array Biopharma logoArray BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.

Receive ARRY News and Ratings via Email

Sign-up to receive the latest news and ratings for ARRY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ARRY
CUSIP04269X10
Phone303-381-6600

Debt

Debt-to-Equity Ratio0.39%
Current Ratio6.17%
Quick Ratio6.17%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$150.85 million
Price / Sales19.88
Cash FlowN/A
Price / CashN/A
Book Value$0.07 per share
Price / Book206.29

Profitability

EPS (Most Recent Fiscal Year)($0.72)
Net Income$-116,810,000.00
Net Margins-98.51%
Return on Equity-107.79%
Return on Assets-36.51%

Miscellaneous

Employees209
Outstanding Shares207,640,000

How to Become a New Pot Stock Millionaire

Array Biopharma (NASDAQ:ARRY) Frequently Asked Questions

What is Array Biopharma's stock symbol?

Array Biopharma trades on the NASDAQ under the ticker symbol "ARRY."

How were Array Biopharma's earnings last quarter?

Array Biopharma Inc (NASDAQ:ARRY) announced its quarterly earnings data on Tuesday, February, 6th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the Zacks' consensus estimate of ($0.23) by $0.06. The biopharmaceutical company had revenue of $42.21 million for the quarter, compared to the consensus estimate of $26.81 million. Array Biopharma had a negative net margin of 98.51% and a negative return on equity of 107.79%. The firm's revenue was down 5.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.14) earnings per share. View Array Biopharma's Earnings History.

When is Array Biopharma's next earnings date?

Array Biopharma is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Array Biopharma.

What price target have analysts set for ARRY?

8 equities research analysts have issued 1-year price targets for Array Biopharma's stock. Their predictions range from $13.00 to $23.00. On average, they anticipate Array Biopharma's share price to reach $17.25 in the next year. View Analyst Ratings for Array Biopharma.

What are Wall Street analysts saying about Array Biopharma stock?

Here are some recent quotes from research analysts about Array Biopharma stock:
  • 1. According to Zacks Investment Research, "Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. " (2/9/2018)
  • 2. Cantor Fitzgerald analysts commented, "ARRY and ASLAN (NC) have updated a 2011 agreement for varlitinib, a pan-HER2 inhibitor, providing nearer term cash to ARRY in exchange for commercialization rights (the prior agreement covered development)." (1/3/2018)

Who are some of Array Biopharma's key competitors?

Who are Array Biopharma's key executives?

Array Biopharma's management team includes the folowing people:
  • Kyle A. Lefkoff, Independent Chairman of the Board (Age 56)
  • Ron R. Squarer, Chief Executive Officer, Director (Age 50)
  • Jason Haddock, Chief Financial Officer (Age 47)
  • Andrew R. Robbins, Chief Operating Officer (Age 41)
  • Nicholas A. Saccomano Ph.D., Chief Scientific Officer (Age 58)
  • Curtis Gale Oltmans, General Counsel (Age 54)
  • Victor Sandor, Chief Medical Officer (Age 51)
  • Shalini Sharp, Director (Age 42)
  • Charles M. Baum M.D., Ph.D., Independent Director (Age 59)
  • Gwendolyn A. Fyfe M.D., Independent Director (Age 65)

Has Array Biopharma been receiving favorable news coverage?

News stories about ARRY stock have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Array Biopharma earned a daily sentiment score of 0.22 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 45.03 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Array Biopharma?

Shares of ARRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Array Biopharma's stock price today?

One share of ARRY stock can currently be purchased for approximately $14.44.

How big of a company is Array Biopharma?

Array Biopharma has a market capitalization of $3.17 billion and generates $150.85 million in revenue each year. The biopharmaceutical company earns $-116,810,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Array Biopharma employs 209 workers across the globe.

How can I contact Array Biopharma?

Array Biopharma's mailing address is 3200 Walnut Street, Boulder CO, 80301. The biopharmaceutical company can be reached via phone at 303-381-6600 or via email at [email protected]


MarketBeat Community Rating for Array Biopharma (ARRY)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  337 (Vote Outperform)
Underperform Votes:  177 (Vote Underperform)
Total Votes:  514
MarketBeat's community ratings are surveys of what our community members think about Array Biopharma and other stocks. Vote "Outperform" if you believe ARRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARRY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Array Biopharma (NASDAQ:ARRY) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Array Biopharma in the last 12 months. Their average twelve-month price target is $17.25, suggesting that the stock has a possible upside of 19.46%. The high price target for ARRY is $23.00 and the low price target for ARRY is $13.00. There are currently 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.882.86
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $17.25$17.25$14.6250$13.8571
Price Target Upside: 19.46% upside1.71% downside7.93% upside22.74% upside

Array Biopharma (NASDAQ:ARRY) Consensus Price Target History

Price Target History for Array Biopharma (NASDAQ:ARRY)

Array Biopharma (NASDAQ:ARRY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/7/2018Leerink SwannBoost Price TargetOutperform -> Outperform$19.00 -> $20.00LowView Rating Details
2/7/2018Stifel NicolausBoost Price TargetBuy -> Buy$20.00 -> $23.00HighView Rating Details
2/6/2018SunTrust BanksReiterated RatingBuy$20.00LowView Rating Details
1/21/2018Cantor FitzgeraldReiterated RatingBuy$15.00LowView Rating Details
12/22/2017Jefferies GroupBoost Price TargetBuy$13.00N/AView Rating Details
9/20/2017Piper JaffrayReiterated RatingOverweight$14.00 -> $18.00LowView Rating Details
9/11/2017CowenReiterated RatingOutperform$14.00 -> $15.00HighView Rating Details
9/11/2017JPMorgan ChaseReiterated RatingBuy$14.00HighView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Array Biopharma (NASDAQ:ARRY) Earnings History and Estimates Chart

Earnings by Quarter for Array Biopharma (NASDAQ:ARRY)

Array Biopharma (NASDAQ:ARRY) Earnings Estimates

2018 EPS Consensus Estimate: ($0.97)
2019 EPS Consensus Estimate: ($0.71)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.31)($0.19)($0.25)
Q2 20182($0.32)($0.18)($0.25)
Q3 20183($0.27)($0.18)($0.21)
Q4 20183($0.29)($0.21)($0.26)
Q1 20191($0.24)($0.24)($0.24)
Q2 20191($0.01)($0.01)($0.01)
Q3 20191($0.23)($0.23)($0.23)
Q4 20191($0.23)($0.23)($0.23)

Array Biopharma (NASDAQ ARRY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018($0.22)N/AView Earnings Details
2/6/2018Q2 2018($0.23)($0.17)$26.81 million$42.21 millionViewN/AView Earnings Details
10/31/2017Q1 2018($0.22)($0.22)$33.74 million$29.75 millionViewN/AView Earnings Details
8/9/2017Q4 2017($0.21)($0.17)$28.64 million$33.80 millionViewListenView Earnings Details
5/10/2017Q3 2017($0.1610)($0.21)$38.28 million$33.28 millionViewN/AView Earnings Details
2/9/2017Q2 2017($0.18)($0.14)$31.90 million$44.50 millionViewListenView Earnings Details
11/1/2016Q117($0.16)($0.20)$32.47 million$39.30 millionViewListenView Earnings Details
8/4/2016Q416($0.14)($0.17)$41.51 million$43.20 millionViewListenView Earnings Details
5/3/2016Q316($0.12)($0.16)$30.35 million$43.00 millionViewListenView Earnings Details
2/2/2016Q216($0.06)($0.17)$32.70 million$35.40 millionViewListenView Earnings Details
11/4/2015Q116($0.18)($0.15)$14.02 million$16.20 millionViewListenView Earnings Details
8/3/2015Q415($0.16)($0.09)$10.29 million$12.30 millionViewListenView Earnings Details
5/4/2015Q315($0.01)$0.37$6.00 million$6.60 millionViewListenView Earnings Details
2/3/2015Q215($0.20)($0.06)$10.20 million$26.92 millionViewListenView Earnings Details
11/4/2014Q115($0.22)($0.21)$6.35 million$6.07 millionViewListenView Earnings Details
8/12/2014Q414($0.23)($0.22)$8.10 million$6.00 millionViewListenView Earnings Details
4/29/2014Q314($0.21)($0.20)$9.40 million$7.80 millionViewListenView Earnings Details
2/4/2014Q214($0.16)($0.13)$13.49 million$14.10 millionViewListenView Earnings Details
10/31/2013Q114($0.18)($0.13)$11.20 million$14.20 millionViewListenView Earnings Details
8/7/2013Q4 2013($0.13)($0.06)$16.13 million$25.40 millionViewListenView Earnings Details
5/6/2013Q3 2013($0.14)($0.19)$14.54 million$10.00 millionViewListenView Earnings Details
2/4/2013Q2 2013($0.14)($0.10)$16.52 million$18.40 millionViewListenView Earnings Details
10/29/2012Q113($0.15)($0.13)$16.70 million$15.80 millionViewN/AView Earnings Details
8/13/2012($0.11)($0.09)ViewN/AView Earnings Details
4/30/2012($0.16)($0.11)ViewN/AView Earnings Details
1/30/2012($0.12)($0.06)ViewN/AView Earnings Details
10/31/2011Q1 2012($0.19)($0.06)ViewN/AView Earnings Details
8/8/2011Q4 2011($0.27)($0.17)ViewN/AView Earnings Details
5/2/2011($0.25)($0.20)ViewN/AView Earnings Details
1/31/2011($0.28)($0.23)ViewN/AView Earnings Details
11/8/2010Q1 2011($0.28)($0.20)ViewN/AView Earnings Details
8/9/2010Q4 2010($0.32)($0.30)ViewN/AView Earnings Details
5/3/2010Q3 2010($0.34)($0.30)ViewN/AView Earnings Details
2/1/2010Q2 2010($0.55)($0.44)ViewN/AView Earnings Details
11/2/2009Q1 2010($0.55)($0.52)ViewN/AView Earnings Details
8/10/2009Q4 2009($0.55)($0.55)ViewN/AView Earnings Details
5/4/2009Q3 2009($0.58)($0.55)ViewN/AView Earnings Details
2/2/2009Q2 2009($0.65)($0.57)ViewN/AView Earnings Details
11/3/2008Q1 2009($0.65)($0.63)ViewN/AView Earnings Details
8/11/2008Q4 2008($0.63)($0.68)ViewN/AView Earnings Details
5/5/2008Q3 2008($0.51)($0.51)ViewN/AView Earnings Details
2/4/2008Q2 2008($0.46)($0.43)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Array Biopharma (NASDAQ:ARRY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Array Biopharma (NASDAQ ARRY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.18%
Institutional Ownership Percentage: 96.38%
Insider Trading History for Array Biopharma (NASDAQ:ARRY)
Institutional Ownership by Quarter for Array Biopharma (NASDAQ:ARRY)

Array Biopharma (NASDAQ ARRY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/18/2018Lunsen Gil J VanDirectorSell21,500$15.19$326,585.0024,797View SEC Filing  
4/3/2018Victor SandorInsiderSell8,689$15.35$133,376.15View SEC Filing  
3/21/2018Lunsen Gil J VanDirectorSell21,500$16.76$360,340.0026,297View SEC Filing  
3/9/2018Victor SandorInsiderSell156,016$17.71$2,763,043.36View SEC Filing  
2/21/2018Lunsen Gil J VanDirectorSell21,500$17.16$368,940.0032,797View SEC Filing  
2/9/2018Charles M BaumDirectorSell50,000$16.90$845,000.0035,000View SEC Filing  
1/17/2018Lunsen Gil J VanDirectorSell21,500$12.94$278,210.0034,297View SEC Filing  
1/16/2018Jason HaddockCFOSell7,500$13.73$102,975.0036,368View SEC Filing  
12/19/2017Ron SquarerCEOSell819,671$10.86$8,901,627.06View SEC Filing  
12/18/2017Andrew R. RobbinsCOOSell282,874$10.72$3,032,409.28View SEC Filing  
9/29/2017Kyle LefkoffDirectorSell38,865$12.31$478,428.1551,585View SEC Filing  
3/28/2017Charles M BaumDirectorSell25,000$9.27$231,750.0030,000View SEC Filing  
9/28/2016Redmile Group, LlcMajor ShareholderSell2,492,578$6.36$15,852,796.08View SEC Filing  
9/15/2016Redmile Group, LlcMajor ShareholderBuy400,000$3.51$1,404,000.00View SEC Filing  
1/20/2016Redmile Group, LlcMajor ShareholderBuy300,000$3.19$957,000.00View SEC Filing  
1/12/2016Redmile Group, LlcMajor ShareholderBuy75,000$3.60$270,000.00View SEC Filing  
1/11/2016Redmile Group, LlcMajor ShareholderBuy925,000$3.67$3,394,750.00View SEC Filing  
10/1/2015Redmile Group, LlcMajor ShareholderBuy782,592$4.58$3,584,271.36View SEC Filing  
8/25/2015Redmile Group, LlcMajor ShareholderBuy790,000$5.38$4,250,200.00View SEC Filing  
8/10/2015Redmile Group, LlcMajor ShareholderBuy1,048,993$5.80$6,084,159.40View SEC Filing  
3/3/2015Kyle LefkoffDirectorSell70,000$8.00$560,000.00View SEC Filing  
3/2/2015Andrews R RobbinsSVPSell21,576$8.25$178,002.00View SEC Filing  
3/2/2015Ron SquarerCEOSell40,000$8.25$330,000.00View SEC Filing  
9/16/2013Liam RatcliffeDirectorSell1,673,172$6.08$10,172,885.76View SEC Filing  
9/6/2013Liam RatcliffeDirectorSell577,286$5.79$3,342,485.94View SEC Filing  
8/2/2013John R MooreVPSell75,384$7.02$529,195.68View SEC Filing  
7/23/2013John R MooreVPSell5,000$6.50$32,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Array Biopharma (NASDAQ ARRY) News Headlines

Source:
DateHeadline
Array Biopharma Inc (ARRY) Expected to Announce Earnings of -$0.22 Per ShareArray Biopharma Inc (ARRY) Expected to Announce Earnings of -$0.22 Per Share
www.americanbankingnews.com - April 19 at 5:39 AM
Array Biopharma Inc (ARRY) Director Lunsen Gil J. Van Sells 21,500 SharesArray Biopharma Inc (ARRY) Director Lunsen Gil J. Van Sells 21,500 Shares
www.americanbankingnews.com - April 18 at 7:28 PM
Array Biopharma (ARRY) Downgraded by BidaskClub to "Strong Sell"Array Biopharma (ARRY) Downgraded by BidaskClub to "Strong Sell"
www.americanbankingnews.com - April 18 at 6:54 PM
Array Biopharma (ARRY) Given Buy Rating at Cantor FitzgeraldArray Biopharma (ARRY) Given Buy Rating at Cantor Fitzgerald
www.americanbankingnews.com - April 17 at 5:25 PM
See what the IHS Markit Score report has to say about Array Biopharma Inc.See what the IHS Markit Score report has to say about Array Biopharma Inc.
finance.yahoo.com - April 16 at 9:57 AM
Array Biopharma Inc (ARRY) Given Consensus Rating of "Buy" by BrokeragesArray Biopharma Inc (ARRY) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 12 at 8:49 AM
Stifel Nicolaus Reaffirms "Buy" Rating for Array Biopharma (ARRY)Stifel Nicolaus Reaffirms "Buy" Rating for Array Biopharma (ARRY)
www.americanbankingnews.com - April 11 at 3:24 PM
Array Biopharma (ARRY) Given a $13.00 Price Target by Cantor Fitzgerald AnalystsArray Biopharma (ARRY) Given a $13.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - April 11 at 12:43 AM
Array Biopharma (ARRY) Earns "Buy" Rating from Piper JaffrayArray Biopharma (ARRY) Earns "Buy" Rating from Piper Jaffray
www.americanbankingnews.com - April 10 at 10:31 PM
Array Biopharma Sees Unusually High Options Volume (ARRY)Array Biopharma Sees Unusually High Options Volume (ARRY)
www.americanbankingnews.com - April 6 at 8:03 AM
 Brokerages Expect Array Biopharma Inc (ARRY) Will Announce Quarterly Sales of $32.07 Million Brokerages Expect Array Biopharma Inc (ARRY) Will Announce Quarterly Sales of $32.07 Million
www.americanbankingnews.com - April 4 at 4:37 AM
Array Biopharma Inc (ARRY) Insider Victor Sandor Sells 8,689 SharesArray Biopharma Inc (ARRY) Insider Victor Sandor Sells 8,689 Shares
www.americanbankingnews.com - April 3 at 10:46 PM
ValuEngine Upgrades Array Biopharma (ARRY) to "Buy"ValuEngine Upgrades Array Biopharma (ARRY) to "Buy"
www.americanbankingnews.com - April 3 at 7:34 PM
Is There An Opportunity With Array BioPharma Inc’s (NASDAQ:ARRY) 32% Undervaluation?Is There An Opportunity With Array BioPharma Inc’s (NASDAQ:ARRY) 32% Undervaluation?
finance.yahoo.com - April 3 at 10:18 AM
Array Biopharmas (ARRY) "Buy" Rating Reiterated at Stifel NicolausArray Biopharma's (ARRY) "Buy" Rating Reiterated at Stifel Nicolaus
www.americanbankingnews.com - April 2 at 3:42 PM
Cantor Fitzgerald Analysts Give Array Biopharma (ARRY) a $15.00 Price TargetCantor Fitzgerald Analysts Give Array Biopharma (ARRY) a $15.00 Price Target
www.americanbankingnews.com - March 30 at 10:36 PM
Array Biopharma (ARRY) Upgraded to Hold at BidaskClubArray Biopharma (ARRY) Upgraded to Hold at BidaskClub
www.americanbankingnews.com - March 29 at 11:17 AM
Leerink Swann Upgrades Array Biopharma (ARRY) to OutperformLeerink Swann Upgrades Array Biopharma (ARRY) to Outperform
www.americanbankingnews.com - March 27 at 10:01 AM
Today’s Research Reports on Trending Tickers: Geron Corporation and Array BioPharma Inc.Today’s Research Reports on Trending Tickers: Geron Corporation and Array BioPharma Inc.
finance.yahoo.com - March 26 at 10:50 AM
Array Biopharma (ARRY) Rating Lowered to Sell at BidaskClubArray Biopharma (ARRY) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - March 23 at 11:20 PM
Array BioPharma Announces Publication of Detailed Phase 3 COLUMBUS Trial Data of Encorafenib and Binimetinib in Melanoma Patients in The Lancet OncologyArray BioPharma Announces Publication of Detailed Phase 3 COLUMBUS Trial Data of Encorafenib and Binimetinib in Melanoma Patients in The Lancet Oncology
finance.yahoo.com - March 22 at 9:52 AM
Insider Selling: Array Biopharma Inc (ARRY) Director Sells 21,500 Shares of StockInsider Selling: Array Biopharma Inc (ARRY) Director Sells 21,500 Shares of Stock
www.americanbankingnews.com - March 21 at 7:32 PM
$31.65 Million in Sales Expected for Array Biopharma Inc (ARRY) This Quarter$31.65 Million in Sales Expected for Array Biopharma Inc (ARRY) This Quarter
www.americanbankingnews.com - March 18 at 11:56 AM
Array Biopharma Inc (ARRY) Receives Consensus Rating of "Buy" from BrokeragesArray Biopharma Inc (ARRY) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 18 at 8:54 AM
Head-To-Head Contrast: Array Biopharma (ARRY) vs. Neuroderm (NDRM)Head-To-Head Contrast: Array Biopharma (ARRY) vs. Neuroderm (NDRM)
www.americanbankingnews.com - March 17 at 7:24 PM
Array Biopharma Inc (ARRY) Expected to Announce Earnings of -$0.21 Per ShareArray Biopharma Inc (ARRY) Expected to Announce Earnings of -$0.21 Per Share
www.americanbankingnews.com - March 16 at 3:08 AM
Array Biopharma Inc (ARRY) Insider Sells $2,763,043.36 in StockArray Biopharma Inc (ARRY) Insider Sells $2,763,043.36 in Stock
www.americanbankingnews.com - March 9 at 6:14 PM
Array BioPharma To Present At The Cowen 38th Annual Healthcare ConferenceArray BioPharma To Present At The Cowen 38th Annual Healthcare Conference
finance.yahoo.com - March 5 at 4:18 PM
Wells Fargo & Company MN Sells 192,639 Shares of Array Biopharma Inc (ARRY)Wells Fargo & Company MN Sells 192,639 Shares of Array Biopharma Inc (ARRY)
www.americanbankingnews.com - March 5 at 3:26 PM
State of Wisconsin Investment Board Has $2.16 Million Holdings in Array Biopharma Inc (ARRY)State of Wisconsin Investment Board Has $2.16 Million Holdings in Array Biopharma Inc (ARRY)
www.americanbankingnews.com - March 4 at 9:32 AM
Swiss National Bank Has $3.95 Million Holdings in Array Biopharma Inc (ARRY)Swiss National Bank Has $3.95 Million Holdings in Array Biopharma Inc (ARRY)
www.americanbankingnews.com - March 4 at 8:23 AM
UBS Asset Management Americas Inc. Buys 1,338,377 Shares of Array Biopharma Inc (ARRY)UBS Asset Management Americas Inc. Buys 1,338,377 Shares of Array Biopharma Inc (ARRY)
www.americanbankingnews.com - March 2 at 7:52 PM
EAM Investors LLC Cuts Stake in Array Biopharma Inc (ARRY)EAM Investors LLC Cuts Stake in Array Biopharma Inc (ARRY)
www.americanbankingnews.com - March 2 at 12:57 PM
Hudson Bay Capital Management LP Grows Stake in Array Biopharma Inc (ARRY)Hudson Bay Capital Management LP Grows Stake in Array Biopharma Inc (ARRY)
www.americanbankingnews.com - March 2 at 12:49 PM
Array Biopharma Inc (ARRY) Short Interest UpdateArray Biopharma Inc (ARRY) Short Interest Update
www.americanbankingnews.com - March 2 at 2:40 AM
Array Biopharma Inc (ARRY) Shares Bought by Schwab Charles Investment Management Inc.Array Biopharma Inc (ARRY) Shares Bought by Schwab Charles Investment Management Inc.
www.americanbankingnews.com - March 1 at 5:15 PM
118,158 Shares in Array Biopharma Inc (ARRY) Purchased by X Square Capital LLC118,158 Shares in Array Biopharma Inc (ARRY) Purchased by X Square Capital LLC
www.americanbankingnews.com - February 27 at 2:35 PM
 Analysts Anticipate Array Biopharma Inc (ARRY) to Post -$0.21 Earnings Per Share Analysts Anticipate Array Biopharma Inc (ARRY) to Post -$0.21 Earnings Per Share
www.americanbankingnews.com - February 27 at 3:26 AM
Array Biopharma Inc (ARRY) Director Sells $368,940.00 in StockArray Biopharma Inc (ARRY) Director Sells $368,940.00 in Stock
www.americanbankingnews.com - February 23 at 6:32 PM
Array BioPharma Inc. (ARRY) Given Average Rating of "Buy" by BrokeragesArray BioPharma Inc. (ARRY) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 21 at 10:50 AM
Array BioPharma (ARRY) Price Target Raised to $20.00Array BioPharma (ARRY) Price Target Raised to $20.00
www.americanbankingnews.com - February 19 at 9:40 PM
Options Traders Expect Huge Moves in Array BioPharma (ARRY) StockOptions Traders Expect Huge Moves in Array BioPharma (ARRY) Stock
finance.yahoo.com - February 16 at 9:30 AM
Zacks.com highlights: Cinemark Holdings, Hasbro, Enova International, Array BioPharma and TechTargetZacks.com highlights: Cinemark Holdings, Hasbro, Enova International, Array BioPharma and TechTarget
finance.yahoo.com - February 14 at 3:22 PM
Array BioPharma Inc. (ARRY) Director Charles M. Baum Sells 50,000 SharesArray BioPharma Inc. (ARRY) Director Charles M. Baum Sells 50,000 Shares
www.americanbankingnews.com - February 12 at 6:32 PM
$31.65 Million in Sales Expected for Array BioPharma Inc. (ARRY) This Quarter$31.65 Million in Sales Expected for Array BioPharma Inc. (ARRY) This Quarter
www.americanbankingnews.com - February 12 at 6:18 AM
Zacks: Brokerages Anticipate Array BioPharma Inc. (ARRY) to Announce -$0.22 EPSZacks: Brokerages Anticipate Array BioPharma Inc. (ARRY) to Announce -$0.22 EPS
www.americanbankingnews.com - February 10 at 9:44 AM
Short Interest in Array BioPharma Inc. (ARRY) Decreases By 15.4%Short Interest in Array BioPharma Inc. (ARRY) Decreases By 15.4%
www.americanbankingnews.com - February 10 at 2:02 AM
Array BioPharma (ARRY) Stock Rating Upgraded by Zacks Investment ResearchArray BioPharma (ARRY) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - February 9 at 6:10 PM
Q3 2018 Earnings Forecast for Array BioPharma Inc. Issued By Leerink Swann (ARRY)Q3 2018 Earnings Forecast for Array BioPharma Inc. Issued By Leerink Swann (ARRY)
www.americanbankingnews.com - February 9 at 11:36 AM
Array BioPharma Inc. (ARRY) Forecasted to Post Q3 2018 Earnings of ($0.27) Per ShareArray BioPharma Inc. (ARRY) Forecasted to Post Q3 2018 Earnings of ($0.27) Per Share
www.americanbankingnews.com - February 9 at 11:36 AM

SEC Filings

Array Biopharma (NASDAQ:ARRY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Array Biopharma (NASDAQ:ARRY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Array Biopharma (NASDAQ ARRY) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.